11.95
4.64%
0.53
After Hours:
11.95
Alumis Inc stock is traded at $11.95, with a volume of 24,494.
It is up +4.64% in the last 24 hours and up +22.69% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
See More
Previous Close:
$11.42
Open:
$11.4
24h Volume:
24,494
Relative Volume:
0.16
Market Cap:
$650.12M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-1.73%
1M Performance:
+22.69%
6M Performance:
+0.00%
1Y Performance:
+0.00%
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Alumis Inc Stock (ALMS) Latest News
New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD - Quantisnow
Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - StockTitan
Alumis (NASDAQ:ALMS) Rating Increased to Strong-Buy at Baird R W - MarketBeat
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Robert W. Baird Begins Coverage on Alumis (NASDAQ:ALMS) - MarketBeat
Baird Initiates Coverage of Alumis (ALMS) with Outperform Recommendation - MSN
Baird starts Alumis coverage with Outperform, $25 target - Investing.com India
Baird starts Alumis coverage with Outperform, $25 target By Investing.com - Investing.com South Africa
When (ALMS) Moves Investors should Listen - Stock Traders Daily
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - MSN
Alumis (NASDAQ:ALMS) Stock Price Down 4.5%Time to Sell? - MarketBeat
Alumis (NASDAQ:ALMS) Trading 3.1% HigherWhat's Next? - MarketBeat
HC Wainwright Estimates Alumis' Q3 Earnings (NASDAQ:ALMS) - MarketBeat
Analysts Set Curbline Properties (NYSE:CURB) PT at $24.19 - Defense World
Ambev (NYSE:ABEV) Now Covered by StockNews.com - Defense World
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside - AOL
Alumis (NASDAQ:ALMS) Shares Gap UpHere's Why - MarketBeat
H.C. Wainwright sets Buy rating on Alumis stock - Investing.com
H.C. Wainwright sets Buy rating on Alumis stock, cites TYK2 inhibitor - Investing.com Australia
H.C. Wainwright sets Buy rating on Alumis stock By Investing.com - Investing.com UK
Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
(ALMS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Shifts in the Psoriasis Market Suggest Strong Potential for Emerging Oral Therapies - GlobeNewswire Inc.
Alumis (NASDAQ:ALMS) Stock Price Down 2.6%What's Next? - MarketBeat
Alumis (NASDAQ:ALMS) Shares Up 6.9%What's Next? - MarketBeat
Millennium Management LLC Takes Position in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' - Benzinga
Cramer's Lightning Round: 'I like Target right here' - CNBC
Uveitis Market Growth to Accelerate in Forecast Period - openPR
Alumis (NASDAQ:ALMS) Trading Up 3.8%Time to Buy? - MarketBeat
(ALMS) Technical Pivots with Risk Controls - Stock Traders Daily
Alumis: Could This Broken Immunology IPO Become The Next Amgen? (ALMS) - Seeking Alpha
Strategy Shares NASDAQ 7 HANDL ETF (NASDAQ:HNDL) is Kades & Cheifetz LLC’s 3rd Largest Position - Defense World
Promising Long-term Results for ESK-001 in Psoriasis - Dermatology Times
Alumis (NASDAQ:ALMS) Stock Price Down 4.8% - MarketBeat
Alumis reports progress in psoriasis treatment trial By Investing.com - Investing.com South Africa
Alumis reports progress in psoriasis treatment trial - Investing.com India
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study - ForexTV.com
ALMSAlumis Inc. Latest Stock News & Market Updates - StockTitan
Creating Equitable AI Models for Multiple Myeloma - AJMC.com Managed Markets Network
Alumis (NASDAQ:ALMS) Trading Up 4.8% - MarketBeat
(ALMS) Technical Data - Stock Traders Daily
Alumis (NASDAQ:ALMS) Shares Gap Down to $11.86 - Defense World
Yu Fan Purchases New Stake in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis Inc. [ALMS] Stock bought by Insider Foresite Labs, LLC for $40.0 million - Knox Daily
Taking on analysts’ expectations and winning: Alumis Inc. (ALMS) - SETE News
SR One Capital Management LP Invests $26.07 Million in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis (NASDAQ:ALMS) Shares Down 2.6% - MarketBeat
Alumis (NASDAQ:ALMS) Trading 5.3% Higher - MarketBeat
Alumis (NASDAQ:ALMS) Stock Price Up 5.3% - Defense World
Alumis (NASDAQ:ALMS) Reaches New 12-Month Low at $10.37 - MarketBeat
Alumis Inc Stock (ALMS) Financials Data
There is no financial data for Alumis Inc (ALMS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):